New data on MIV-818 will be presented at EASL's International Liver Congress™ 2017
Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR ) today informs that preclinical data on MIV-818 will be presented by Medivir at The International Liver Congress™ 2017 of the European Association for the Study of the Liver (EASL) in Amsterdam, on 19-23 April. The poster presentation, abstract SAT-123, is entitled “Liver-targeting with the novel nucleotide prodrug MIV-818 designed for the treatment of liver cancers” and will include data on the anticancer activity and pharmacokinetic profile of MIV-818.
Details of all presentations for The International Liver Congress™ 2017 are available at the website: http://www.easl.eu/ .
For further information, please contact:
Richard Bethell, CSO Medivir AB, mobile +46 (0)72-704 3211
Ola Burmark, CFO Medivir AB, mobile: +46 (0) 725 480 580
Medivir develops innovative pharmaceutical products for the treatment of cancer. The company specialises in protease inhibitor research and nucleotide/nucleoside science and conducts research in all stages of the drug development process, from original idea to clinical phase III studies. Its development work is done both in-house and through partnerships.